Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

作者：Mariano Provencio, Manuel Cobo, Delvys Rodríguez‐Abreu, Virginia Calvo, Enric Carcereny, Alexandra Cantero, Reyes Bernabé, Gretel Benítez, Rafael López Castro, Bartomeu Massutí, E. del Barco, Rosario García Campelo, M. Guirado, Carlos Camps, Ana Laura Ortega Granados, J.L. González-Larriba, Alfredo Sánchez, J. Casal, M.A. Sala, Óscar Juan, Joaquim Bosch‐Barrera, Juana Oramás, Manuel Dómine, José Trigo, Remei Blanco, Julia Calzas, Idoia Morilla, Airam Padilla, J. Pimentão, Pedro Sousa, María Torrente · 发表于：BMC Cancer · 年份：2022 · DOI：10.1186/s12885-022-09830-8 · 被引用次数：17 · 研究领域：Lung Cancer Treatments and Mutations、Cancer Immunotherapy and Biomarkers、Lung Cancer Diagnosis and Treatment

BACKGROUND: The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself. This work aims to study the situation of biomarker testing in Spain. PATIENTS AND METHODS: The Thoracic Tumours Registry (TTR) is an observational, prospective, registry-based study that included patients diagnosed with lung cancer and other thoracic tumours, from September 2016 to 2020. This TTR study was sponsored by the Spanish Lung Cancer Group (GECP) Foundation, an independent, scientific, multidisciplinary oncology society that coordinates more than 550 experts and 182 hospitals across the Spanish territory. RESULTS: Nine thousand two hundred thirty-nine patients diagnosed with stage IV non-small cell lung cancer (NSCLC) between 2106 and 2020 were analysed. 7,467 (80.8%) were non-squamous and 1,772 (19.2%) were squamous. Tumour marker testing was performed in 85.0% of patients with non-squamous tumours vs 56.3% in those with squamous tumours (p-value < 0.001). The global testing of EGFR, ALK, and ROS1 was 78.9, 64.7, 35.6% respectively, in non-squamous histology. PDL1 was determined globally in the same period (46.9%), although if we focus on the last 3 years it exceeds 85%. There has been a significant increase in the last few years of all determinations and there are even close to 10% of molecular determinations that do not yet h...